Cumberland Pharmaceuticals CPIX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.13M-22.0% | $13.68M+31.1% | $8.29M-8.7% | $10.84M+10.0% | $11.71M+37.8% | ||
| $1.93M+35.6% | $2.24M+13.4% | $988.76K-25.3% | $2.01M+17.6% | $1.43M-9.5% | ||
| $7.2M-30.0% | $11.44M+35.2% | $7.3M-5.9% | $8.83M+8.5% | $10.29M+48.6% | ||
| 78.8%-9.0pp | 83.6%+2.6pp | 88.1%+2.6pp | 81.4%-1.2pp | 87.8%+6.4pp | ||
| $1.46M+12.6% | $1.55M+19.9% | $1.25M-4.0% | $1.47M+38.6% | $1.3M+11.8% | ||
| $5.06M+19.7% | $6.21M+47.0% | $4.43M+0.8% | $4.22M-0.6% | $4.23M+1.9% | ||
| $2.55M+3.7% | $4.04M+21.4% | $2.57M-3.9% | $2.87M+4.3% | $2.46M+4.0% | ||
| $1.25M+24.2% | $1.01M-30.6% | $1.01M-6.4% | $1.01M-8.5% | $1.01M-9.5% | ||
| $12.26M+17.7% | $15.05M+22.6% | $10.26M-4.8% | $11.58M+6.5% | $10.42M+0.5% | ||
| -$3.13M-342% | -$1.37M+25.6% | -$1.97M-16.0% | -$747.48K+27.2% | $1.29M+169% | ||
| -34.3%-45.3pp | -10%+7.6pp | -23.7%-5.1pp | -6.9%+3.5pp | 11%+33.0pp | ||
| $85.84K-47.6% | $112.94K-49.4% | $109.7K-20.1% | $109.55K-13.3% | $163.8K+38.2% | ||
| $78.03K-37.9% | $91.97K-13.8% | $131.58K+90.2% | $127.49K+106% | $125.71K+29.9% | ||
| -$146.08K— | —— | —— | —— | $0— | ||
| -$3.14M-350% | -$1.39M+28.9% | -$1.94M-27.4% | -$729.54K+33.1% | $1.25M+166% | ||
| $3.87K-31.7% | $23.25K+141% | $5.67K-50.4% | $5.67K-50.4% | $5.67K-50.4% | ||
| -$3.29M-362% | -$1.41M+25.8% | -$1.94M-25.7% | -$740.74K+31.8% | $1.26M+165% | ||
| -36%-46.8pp | -10.3%+7.9pp | -23.4%-6.4pp | -6.8%+4.2pp | 10.7%+33.6pp | ||
| -$0.22-375% | -$0.09+35.7% | -$0.13-18.2% | -$0.05+37.5% | $0.08+157% | ||
| -$0.22-375% | -$0.09+35.7% | -$0.13-18.2% | -$0.05+37.5% | $0.08+157% | ||
| 15M-2.0% | 14.9M+5.6% | 15M+6.4% | 15M+6.0% | 15.3M+8.2% | ||
| 15M+0.1% | 14.9M+5.6% | 15M+6.4% | 15M+6.0% | 14.9M+6.0% | ||
| $1.25M+24.2% | $1.01M-30.6% | $1.01M-6.4% | $1.01M-8.5% | $1.01M-9.5% | ||
| $9.13M-22.0% | $13.68M+31.1% | $8.29M-8.7% | $10.84M+10.0% | $11.71M+37.8% | ||
| -$3.13M-342% | -$1.37M+25.6% | -$1.97M-16.0% | -$747.48K+27.2% | $1.29M+169% | ||
| -$1.85M-180% | -$329.31K+4.7% | -$927.46K-60.3% | $286.44K+154% | $2.32M+423% | ||
| -$1.85M-180% | -$329.31K+4.7% | -$927.46K-60.3% | $286.44K+154% | $2.32M+423% | ||
| -20.3%-40.1pp | -2.4%+0.9pp | -11.2%-4.8pp | 2.6%+1.5pp | 19.8%+28.3pp | ||
| -$3.13M-342% | -$1.37M+25.6% | -$1.97M-16.0% | -$747.48K+27.2% | $1.29M+169% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cumberland Pharmaceuticals's revenue?
- Cumberland Pharmaceuticals (CPIX) generated $41.9M in revenue over the trailing twelve months, up 2.1% year over year.
- Is Cumberland Pharmaceuticals profitable?
- Cumberland Pharmaceuticals is not currently profitable: it reported a net loss of $7.4M over the trailing twelve months, a -17.6% net margin.
- What are Cumberland Pharmaceuticals's profit margins?
- Gross margin is 82.9% and operating margin is -17.2%, with a -17.6% net margin.
- What is Cumberland Pharmaceuticals's earnings per share?
- Cumberland Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.49.
- Where does Cumberland Pharmaceuticals's income statement data come from?
- Every line is extracted from Cumberland Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
